Biotech Values

[iwfal]

SNTA -

Also, he insinuated that the data in these subpopulations is way better than mere doubling of the PFS even though he admits that he has not seen the data

.

Will have to listen - but are you sure it was an insinuation wrt PFS or was it more of an insinuation about a nebulous 'endpoint'. (The ORR data aligns better with how recently the trial started.)

NOTES:

1) I corrected the post in an edit because I misremembered the primary endpoint as being ORR.

2) They just updated (5/2/2012) the endpoints on Clinical Trials (removing Survival in high-LDH population, and updating primary endpoint to be PFS in two subpopulations)